Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
EXEL recorded earnings of 17 cents per share, which missed the Zacks Consensus Estimate of 28 cents. The company registered adjusted earnings of 16 cents per share in the first quarter of 2023. Including stock-based compensation expense, EPS was 12 cents, flat year over year. Net revenues were $425.2 million, which lagged the Zacks Consensus Estimate of $468 million. The top line, however, increased 4% year over year. Exelixis' shares have lost 2.2% year to date compared with the industry's decline of 9.6%. Image Source: Zacks Investment Research Quarter in Detail Net product revenues came in at $378.5 million, up 4.1% year over year. The increase in net product revenues was primarily due to a rise in sales volume, partially offset by a decrease in average net selling price. Cabometyx (cabozantinib) generated revenues of $376.4 million, which missed the Zacks Consensus Estimate and our model estimate of $427 million and $413.4 million, respectively. The drug is approved
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Stephens. They set an "equal weight" rating and a $23.00 price target on the stock.MarketBeat
- Exelixis files patent suit against India's Cipla over Cabometyx generics [Seeking Alpha]Seeking Alpha
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in MayBusiness Wire
- Exelixis (EXEL) International Revenue Performance Explored [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 4/30/24 - Miss
EXEL
Sec Filings
- 5/13/24 - Form 144
- 5/10/24 - Form 8-K
- 5/8/24 - Form SC
- EXEL's page on the SEC website